Results 111 to 120 of about 51,155 (263)
Summary of pregnancy management in CTD‐ILD across preconception, antenatal, and postpartum phases, emphasizing risk stratification and multidisciplinary care. 6MWT, 6‐min walk test; CTD‐ILD: connective tissue disease‐interstitial lung disease; DLCO, diffusion capacity of the lung for carbon monoxide; FVC, forced vital capacity; MDT, multidisciplinary ...
Khaled Aldhuaina +3 more
wiley +1 more source
Prompt recurrence of granuloma annulare upon Janus kinase inhibitor discontinuation. [PDF]
Haveric A, Zhao P, Markeson CD, Hsu S.
europepmc +1 more source
Infection risk in rheumatoid arthritis patients treated with biologic and targeted therapies
In this context, infections associated with each biologic and targeted drug are summarized to inform the stratification of RA patients, including the characteristics of the susceptible patients and their concomitant therapy. We aim to provide a benefit‐risk analysis for clinical decision, and vital indications for the prevention of highly correlated ...
Lujing Wang, Jieshi Lin, Jie Qian
wiley +1 more source
Use of Janus Kinase Inhibitor Upadacitinib in Microscopic Colitis. [PDF]
Mumm B, Stein DJ.
europepmc +1 more source
Cancer nanovaccines have emerged as promising alternatives to conventional cancer vaccines, which have shown limited clinical efficacy. In particular, cell membrane nanoparticle‐based nanovaccines can offer high biocompatibility and immunogenicity while preserving tumor antigens, including antigen repertoires.
Munsik Kim, Ilkoo Noh
wiley +1 more source
Resolution of Hashimoto thyroiditis with Janus kinase inhibitor therapy in a patient with alopecia universalis. [PDF]
Trost SU, Radulescu A.
europepmc +1 more source
Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley +1 more source
Diversifying the triquinazine scaffold of a Janus kinase inhibitor. [PDF]
Mulliri K +5 more
europepmc +1 more source
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter +20 more
wiley +1 more source

